Who Paid My Doc
Jennifer Schwartz
Obesity Medicine Needham, MA Medical Doctor
NPI 1447431713 CMS profile 945328
163 Highland Ave, #1247, Needham, MA 02494
General payments
$1,407
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$3,130
Through program year 2025, Jennifer Schwartz of Needham, MA is reported in the CMS Open Payments database as having received $1,407 across 23 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,130 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 63rd percentile of Obesity Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $564 | 1 | |
| 2023 | General | $187 | 8 | |
| 2021 | General | $106 | 1 | |
| 2020 | General | $38 | 1 | |
| 2019 | General | $512 | 12 |
Beside peers
- Jennifer Schwartz
- Obesity Medicine median
- Middle half of Obesity Medicine
- National median
In program year 2025, general payments to Jennifer Schwartz were reported at $564. Among 72 Obesity Medicine profiles paid that year, the median was $191 and the middle half received between $116 and $2,515.
Show as a table
| Year | Jennifer Schwartz | Obesity Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $512 | $224 | $90–$564 | $163 |
| 2020 | $38 | $118 | $51–$1,043 | $114 |
| 2021 | $106 | $195 | $98–$1,394 | $132 |
| 2022 | $0 | $223 | $87–$754 | $149 |
| 2023 | $187 | $228 | $103–$1,114 | $160 |
| 2024 | $0 | $150 | $83–$471 | $164 |
| 2025 | $564 | $191 | $116–$2,515 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
671
Drug cost
$410,255
Branded share of claims
92.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 152 | $184,274 | |
| Wegovy Semaglutide | Brand | 72 | $113,657 | |
| Mounjaro Tirzepatide | Brand | 78 | $96,469 | |
| Trulicity Dulaglutide | Brand | 11 | $12,366 | |
| Metformin Hcl Er Metformin Hcl | Brand | 309 | $3,222 | |
| Topiramate | Generic | 49 | $267 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 10 billing codesPaid by Medicare
$60,036
Medicare patients
153
Services billed
700
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 57% | |
| Depression | 43% | |
| Diabetes | 39% | |
| Ischemic heart disease | 21% | |
| Chronic kidney disease | 20% | |
| Atrial fibrillation | 17% | |
| Cancer | 14% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
23 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Obesity Medicine in Massachusetts
Related records
Obesity Medicine in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Obesity Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.